Influence of several peptidase inhibitors on the pro-inflammatory effects of substance P, capsaicin and collagenase.
Injection of substance P (SP) in a rat hindpaw induced extravasation of 125I-labelled albumin in both hindpaws and salivation. Intravenous injection of SP dose-dependently increased vascular permeability. This latter effect was increased in rat paws by captopril, an inhibitor of angiotensin-converting enzyme (ACE), administered locally in combination with diprotin A, an inhibitor of an dipeptidyl(amino)peptidase IV (DAP IV) or phosphoramidon, an inhibitor of neutral endopeptidase (NEP). The increase in permeability induced by SP was inhibited by RP 67580, a NK-1-receptor antagonist. Intravenous injection of capsaicin induced labelled albumin extravasation in rat paws. This effect was increased by combination of captopril with diprotin A or phosphoramidon, but not by captopril associated with amastatin, an inhibitor of aminopeptidase M (AmM). It was suppressed by RP 67580. Injection of collagenase in rat paws triggered a swelling and a local plasma exudation. These responses were reduced by RP 67580 but not by RP 68651, its inactive enantiomer. They were increased by combination of captopril with diprotin A or phosphoramidon in normal rats. The potentiating effects of captopril and diprotin A were suppressed by RP 67580 in normal rats but did not develop in kininogen-deficient rats. The oedema induced by collagenase was also increased by lisinopril, another ACE inhibitor, administered locally in combination with apstatin, an inhibitor of aminopeptidase P (AmP). In rats pretreated by methysergide, collagenase-induced oedema was reduced and can be increased by captopril, by lisinopril, administered alone or by lisinopril associated with apstatin. It is concluded that SP is mainly inactivated in rat paws by ACE, DAP IV and NEP. In collagenase-induced oedema, a low amount of SP would be released from afferent nerve terminals by bradykinin formed in low amounts. Bradykinin is inactivated in rat paws by ACE and AmP. In collagenase-oedema, the pro-inflammatory effects of bradykinin are concealed by the effects of the other mediators.
Damas
J
J
Department de Physiologie humaine, Université de Liège, Belgium.
Bourdon
V
V
Liégeois
J F
JF
Simmons
W H
WH
D000418:Albumins / Q000378:metabolism; D000704:Analysis of Variance; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001920:Bradykinin / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects*; D002211:Capsaicin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D002216:Captopril / Q000037:antagonists & inhibitors / Q000494:pharmacology; D017364:Collagenases / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000139:chemically induced / Q000378:metabolism; D006020:Glycopeptides / Q000494:pharmacology; D006614:Hindlimb / Q000187:drug effects; D007211:Indoles / Q000494:pharmacology; D007249:Inflammation / Q000503:physiopathology; D054833:Isoindoles; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D008784:Methysergide / Q000494:pharmacology; D064729:Neurokinin-1 Receptor Antagonists; D009842:Oligopeptides / Q000494:pharmacology; D009929:Organ Size / Q000187:drug effects; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012702:Serotonin Antagonists / Q000494:pharmacology; D013373:Substance P / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*
D000418:Albumins; D000806:Angiotensin-Converting Enzyme Inhibitors; D006020:Glycopeptides; D007211:Indoles; D054833:Isoindoles; D061965:Matrix Metalloproteinase Inhibitors; D064729:Neurokinin-1 Receptor Antagonists; D009842:Oligopeptides; D011480:Protease Inhibitors; D012702:Serotonin Antagonists; C071693:7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; D013373:Substance P; C041445:diprotin A; D002216:Captopril; D017364:Collagenases; D002211:Capsaicin; D001920:Bradykinin; C008890:phosphoramidon; D008784:Methysergide